A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants

Clinical trial NCT04812548 · TERMINATED

Trial details

NCT number: NCT04812548
Sponsor: Novartis Pharmaceuticals
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Myelodysplastic Syndrome (MDS)

Start date: 2021-05-31
Primary completion: 2023-05-08
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.